I don’t agree in a buy-out. You give up so much
I don’t agree in a buy-out. You give up so much potential. We as investors don’t need the help and we will cross that finish line. For me... that is happening as we speak behind the scenes as we don’t know what is happening and Cytodyn can’t divulge everything if the government is somehow involved behind the scenes with an approval. Myself I believe they are aware of where we are. Take the Medicare and Medicaid billing numbers by name written in for Cytodyn. This is only a little smoke but has some creative thinking possibly going on that we don’t know about.
At this point we don’t need a buy out to further our process. We are on the cusp of greatness and it would only reduce our investment to share the potential with another pharmaceutical company by selling out. I am not a proponent of a fast nickel when a slow dime is just around the corner. I don’t believe it’s going to be a slow dime either is going to be a wind fall of dimes... giving up a potential of something amazing like Vyrologix is like giving up an early stock like Microsoft or Apple and taking a few thousand dollars for what could be millions of dollars.
To me... I look at inflammation as the single worst symptom of most diseases and what does Leronlimab do? Reduce inflammation. How does this happen? It stops the inflammation by stopping the immune response. So we have an amazing drug that regulates the immune system and stops the immune system from attacking the victim and does this all with unmatched safety. When you look at the action of this little molecule. You have to see that this method of action could very well work for many diseases. Stopping them cold in their tracks. With all this potential I will wait for the best return an investor can hope for. The new Amazon type investment is Cytodyn. 3-5 years from now... we will all be laughing at the thought of what if... what if we would of sold out or been bought out. When we are traveling the world with all the money from our Vyrologix investment that helped Vyrologix help to make the world become a Safe place again. Especially if we become a vaccine booster to lengthen the time of vaccine that might only be good for 6 months or so. Covid could be huge for us if that happen. But even if it doesn’t. There are many ways looking forward that you can see this drug being a blockbuster for not just one indication. But for many blockbuster indications. Call me greedy... I don’t want to share that with other big pharmaceutical companies when we don’t have to. We are on the cusp of something great. But that’s just my opinion. You others can have your opinions. It wouldn’t take away from my beliefs and I will hold Vyrologix for that 3-5 years and still keep a large share invested forever.
11
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Bringing New Leadership to Charter Next Generation It's an intriguing time to be watching Charter Next Generation (CNG) as they just added a heavyweight to their executive team. Todd Herndon, a veteran with more than three decades of financial savvy, steps in as their new Chief Financial Officer. This is like a football team drafting a star quarterback right before the...
Continue Reading
A Fresh Start for Young Careers with CareerPath You remember the time in life when we thought just having a degree meant something? Well, the game’s changed, and now it’s a twisted jungle where young folks struggle to find their footing. Partners International, a name I’m no stranger to—known for their human capital wizardry—seems to have noticed this chaotic...
Continue Reading
Remember the days when the FBI felt like a mythical fortress of surveillance and high-tech wizardry? Today, we're seeing one of its key veterans, Marcus Thomas, take a different path—a path that's as gritty and necessary as any Wall Street hustle. He's jumping onto the board of Re-fined, a Denver nonprofit aiming to give survivors of sexual exploitation and human...
Continue Reading
ViewScan's Latest Step in AI-Powered Monitoring Long Island's own ViewScan just kicked up some dust in the AI-based monitoring scene. This outfit is rolling out a new release of its ViewScan Protect software, fortified with advanced analytics aimed at beefing up security and operational efficiency. Now, before you gloss over this news as just another tech update, let me...
Continue Reading
iFranchise's Unyielding Dominance in Franchise Consulting Five seconds in the franchise game, and you'd know that staying on top is a grind. But when you're iFranchise Group, it seems like the eighth time is the charm—if there ever was a need for luck. These folks have secured the number one spot in Entrepreneur magazine's Top Franchise Suppliers ranking yet again....
Continue Reading
Reimagining Streaming: GRAI Buys Hangout FM The music streaming game has just been dealt a fresh hand. GRAI, an AI-driven music company, has snatched up Hangout FM, looking to ignite a social revolution in how we experience music. Sitting here, I'm thinking about all those playlists we've built but never truly shared. This acquisition might just change that by combining...
Continue Reading
Unifying Molecular Diagnostics for Better Cancer Care In the chaos of today’s healthcare, Aranscia is aiming to rewrite the book on how we handle cancer diagnostics by teaming up with Northside Hospital Cancer Institute. Now, instead of fumbling through disconnected systems, they plan to glue the pieces together with a blend of their own and borrowed tech. This...
Continue Reading
CEER's Ambitious Leap in Automotive Innovation There's a new kid on the automotive block, and it's making some serious noise. Straight out of Jeddah, CEER has just taken the wraps off their flagship electric sedan and SUV, dubbed the EXOBOT. No small beans here—this is a full-throttle, Saudi-driven pitch into the global automotive circus. And why not? There's oil in...
Continue Reading
Pharmacy Certification Made Easy When ScriptSafe rolled out its certification service for pharmacies, it felt like the industry's straitjacket was finally coming off. We’re talking about a process that traditionally took months, cost a small fortune, and made pharmacies fill out forms like they were honing a doctoral thesis. But now, you've got ScriptSafe offering a...
Continue Reading
Pioneering Leadership for Children's Brain Tumor Network In a world where every advance in pediatric oncology can make a measurable difference, the Children's Brain Tumor Network (CBTN) has just unveiled quite the ace up its sleeve: Dr. Sarah Leary. She's stepping in as Co-Chair of its Executive Board, taking the reins alongside Brian Rood, MD. With extensive experience...
Continue Reading
Top 5 Most Recently Viewed Articles
Verint Faces Challenges in Latest Earnings Report This morning, U.S. stock futures displayed a mixed picture, with the Nasdaq down approximately 50 points. Among the companies experiencing a downturn in pre-market trading is Verint Systems Inc. (NASDAQ: VRNT), which saw a notable decline after revealing its financial results for the second quarter. Financial Goals Not...
Continue Reading
Lloyds Banking Group's Strategic Move Toward Cloud Efficiency In a noteworthy development, Lloyds Banking Group has embarked on an expansive collaboration with Oracle. This strategic partnership focuses on adopting innovative cloud technologies to enhance its customer service and operational efficiency. Enhancing Digital Transformation Primarily, Lloyds is integrating...
Continue Reading
Filament Health's Operational Achievements in 2025 Filament Health Corp. (OTC: FLHLF) is making significant strides in the field of natural psychedelic drug development. In a recent announcement, the company reported impressive operational achievements and financial results for Q3 2025. Quarterly Highlights that Matter One of the most notable accomplishments this quarter...
Continue Reading
Join the Bumble Inc. Securities Class Action Opportunity Investors in Bumble Inc. find themselves at a crucial juncture as a class action lawsuit looms over the company. The Schall Law Firm, a prominent name in shareholder rights litigation, has taken notice of claims concerning Bumble's alleged securities fraud. The lawsuit highlights significant violations of the...
Continue Reading
Northstar Expands Its Product Portfolio Northstar Clean Technologies Inc. (TSXV: ROOF) (OTCQB: ROOOF), based in Canada, has successfully integrated limestone recovery into its operations. This strategic move adds a fourth product line, fortifying the company's position in the sustainable materials market. The limestone recovery process is part of Northstar's innovative...
Continue Reading